CN1117563C - Analgesic composition for cancers in digestive system - Google Patents
Analgesic composition for cancers in digestive system Download PDFInfo
- Publication number
- CN1117563C CN1117563C CN 99107333 CN99107333A CN1117563C CN 1117563 C CN1117563 C CN 1117563C CN 99107333 CN99107333 CN 99107333 CN 99107333 A CN99107333 A CN 99107333A CN 1117563 C CN1117563 C CN 1117563C
- Authority
- CN
- China
- Prior art keywords
- injection
- present
- pain
- cancer
- digestive system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention relates to a digestive system cancer antalgic drug composition. Pilocarpine nitrate and neostigmine methyl sulfate are prepared into injection liquid in certain proportion. The injection liquid of the present invention is used for treating the cancers of the digestive systems including the intestine, the gullet, the liver and the stomach and has the advantages of good and lasting antalgic effect, small dosage, quick effect taking, small side effect and no addiction. Through clinical tests, total effective rate reaches more than 98%, and the present invention is an ideal drug which realizes the goal of 'making patients with cancer not be pained in 2000'.
Description
The invention belongs to pharmaceutical product, or rather, is a kind of injection for the treatment of cancer in digestive system pain.
At present, treating the fierce pain that cancer pain comprises cancer in digestive system pain, particularly middle and terminal cancer both at home and abroad, generally all is to adopt medicines such as dolantin, morphine, aspirin, indometacin.Analgesia such as dolantin, morphine medicine, pain relieving is in short-term used always invalid and toxic and side effects is big, and expense is higher, the easy addiction of patient; Aspirin, indometacin can be alleviated slight cancer pain, and be invalid to moderate or severe cancer pain, and stomach is had strong impulse.The introduction of relieving pain of cancer disease Chinese medicine preparation such as the relieving pain of cancer disease medicine with prepared from traditional Chinese medicines such as Sanguis Draxonis, Concha Arcae, Camphora, Borneolum Syntheticum, succinums that the CN1142961A patent application proposes are also arranged in addition.
The purpose of this invention is to provide a kind of digestive system cancer analgesic pharmaceutical composition that comprises intestinal, esophagus, liver, stomach.
Main technical schemes of the present invention: with pilocarpine nitrate (claiming pilocarpine again) and the mixed by a certain percentage injection that gets of neostigmine methylsulfate.
Analgesic composition for cancers in digestive system of the present invention is by pilocarpine nitrate and neostigmine methylsulfate.And water for injection constitutes, and its content can be by the neostigmine methylsulfate that contains 1-2mg pilocarpine nitrate and 0.2-0.5mg in the 1ml injection, and surplus is that water for injection is formulated.
The pilocarpine nitrate injection prepared and neostigmine methylsulfate injection can be prepared or be bought from the market to the present composition according to a conventional method by required amount mixed preparing.
The using method of injection of the present invention: inject 1-2 every day, per injection liquid consumption: contain pilocarpine nitrate 2-4mg, neostigmine methylsulfate 0.2-0.5mg, adopt intramuscular injection.There are heart or the disease patient of pulmonary to forbid injection of the present invention.
The main in the past preparation medicament for the eyes of pilocarpine nitrate of the present invention, as ophthalmology myosis (poplar algae great mansion chief editor, " medical drugs Neo-Confucianism ", in October, 1984 second edition), generally be not used in other treatment of diseases, the treatment of the cancer pain that more was out of use.
In being used for the treatment of operation back flatulence, bladder contraction is unable usually for neostigmine methylsulfate of the present invention.
Advantage of the present invention and effect.
Injection of the present invention has better pain relieving effect, and is good and lasting as hepatocarcinoma, esophageal carcinoma etc. are compared analgesic effect with A Si sheet woods, dolantin, can addiction, and dosage is little and produce effects is fast, and side effect is little.Pain 51 examples that cause with injection for treating cancer in digestive system of the present invention, wherein hepatocarcinoma 29 examples, rectal cancer 12 examples, esophageal carcinoma 7 examples, colon cancer 3 examples; Oldest 75 years old, minimum 37 years old; Except that hepatocarcinoma is that all the other cases were all made a definite diagnosis through pathological examination, all belong to terminal cancer methods such as B ultrasonic, CT, blood examination were made a definite diagnosis, all have an intense pain, after injecting injection of the present invention, the pain complete obiteration has 23 examples to stubbornly refusing to ache the person, the big alleviation person of pain (hypodynia is arranged) 27 examples, total effective rate is more than 98%, and the pain recurrence is still effective during the reuse medicine after the drug withdrawal, and not needing escalated dose, severe pain takes place in none example during the medication.Pharmaceutical composition of the present invention has the social meaning of reality to the target that realizes " cancer patient not being ached in 2000 " that World Health Organization (WHO) proposes.
Further specify characteristics of the present invention below by instantiation.
Example 1
To contain 2mg pilocarpine nitrate injection (production of Tianjin people pharmaceutical factory) and contain the commercially available neostigmine methylsulfate injection of 0.5mg and be hybridly prepared into injection of the present invention.
Example 2
This example is to use the injection of example 1 preparation to digestive system relieving pain of cancer disease clinical trial situation.
(1) Lee * *, man, 67 years old, suffered from multiple hepatocarcinoma 3 months, severe pain can not be fallen asleep unbearably, the pain increased with antibiotics or transfusion, and commercially available antalgica is invalid with dolantin, adopt injection of the present invention after, one day twice, intramuscular injection, all antalgicas of stopping using simultaneously, medication pain relief after three days, pain disappears after six days, and is dead after two months, not painful till death.
(2) Li Shi, the woman, 75 years old, suffered from rectal cancer 4 months, dyschesia, pain unbearably can not sitting, degree depletion to the utmost during diagnosis and treatment.Inject injection of the present invention, one day twice, all antalgicas of stopping using simultaneously.18 days pain of continuous use disappears, and is without any side effects, dead after half a year, do not have pain till death and take place.
(3) Wang Shi, the woman 73 years old, suffered from esophagus hypomere cancer 4 months, pharynx meal difficulty, acute painful can not falling asleep.Use injection of the present invention, pain disappears after twice, three day on the one, drug withdrawal for some reason after four days, and pain recurrence after month, injection injection of the present invention, pain relief after three days are recovered in the back.
Claims (2)
1. analgesic composition for cancers in digestive system, it is characterized in that be by effective ingredient (A) pilocarpine nitrate and (B) neostigmine methylsulfate and pharmaceutically useful carrier be mixed with the injection that is used for intramuscular injection, described carrier is a water for injection.
2. according to the described compositions of claim 1, it is characterized in that containing in the 1ml injection effective composition (A) chemical compound 1-2mg and (B) chemical compound 0.2-0.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99107333 CN1117563C (en) | 1999-05-17 | 1999-05-17 | Analgesic composition for cancers in digestive system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99107333 CN1117563C (en) | 1999-05-17 | 1999-05-17 | Analgesic composition for cancers in digestive system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1273823A CN1273823A (en) | 2000-11-22 |
| CN1117563C true CN1117563C (en) | 2003-08-13 |
Family
ID=5272717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99107333 Expired - Fee Related CN1117563C (en) | 1999-05-17 | 1999-05-17 | Analgesic composition for cancers in digestive system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1117563C (en) |
-
1999
- 1999-05-17 CN CN 99107333 patent/CN1117563C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1273823A (en) | 2000-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5589480A (en) | Topical application of opioid analgesic drugs such as morphine | |
| Bone et al. | Ginger root—a new antiemetic The effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery | |
| US4006224A (en) | Method and agent for treating inflammatory disorders of the gastrointestinal tract | |
| WO2011098539A1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| CN101622014A (en) | Improved medicinal compositions comprising buprenorphine and naltrexone | |
| US6787149B1 (en) | Topical application of opioid analgesic drugs such as morphine | |
| KR19980014498A (en) | Rich-sulfur combination preparation | |
| CN102824595A (en) | Traditional Chinese medicine composition for treating cancer ache | |
| CN1117563C (en) | Analgesic composition for cancers in digestive system | |
| CN107496525A (en) | A kind of Chinese medicine composition for treating cancer pain disease and its application | |
| Hilker | Agranulocytosis from Tripelennamine (Pyribenzamine®) Hydrochloride | |
| Kumar et al. | Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms | |
| CN1058154C (en) | Medicine for treatment of pile | |
| CN104983829B (en) | A kind of Traditional Chinese medicine compound composition for treating ulcerative colitis and preparation method thereof and preparation | |
| JP2726165B2 (en) | Shampoo composition | |
| CN1132596C (en) | Chinese medicine 'Zhidakang' for treating haemorrhoids and its preparing process | |
| CN108853246B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN106214906B (en) | Medicinal composition for treating bromhidrosis and preparation method thereof | |
| Hurd | Consumption in New England | |
| Merck & Co | Merck's Manual of the Materia Medica | |
| CN117205233A (en) | Natural ocean product composition for relieving morphine tolerance | |
| Tennant Jr | (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids | |
| Turner et al. | Drugs Handbook | |
| UA146317U (en) | MEDICINE IN PARENTERAL PHARMACEUTICAL FORM | |
| CN114306357A (en) | Application of glycyrrhizic acid or its derivative in preparing medicine for treating retinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |